Chronic diseases

AFib After Ablation: Drug Combination Cuts Recurrence Risk From 28% to 18%

Published: · Русский · O‘zbekcha

AHA Scientific Sessions 2026 (Nov 8): sacubitril/valsartan after catheter ablation reduced AFib recurrence to 18% vs 28.3% with valsartan alone in a 320-patient randomized trial of adults with hypertension.

Atrial fibrillation (AFib) is an irregular heart rhythm that can cause a fluttering sensation in the chest, shortness of breath, fatigue, and chest discomfort. Catheter ablation treats small areas of heart tissue that generate abnormal electrical signals — but AFib can recur after the procedure, partly because high blood pressure continues to cause structural changes.

A randomized trial followed 320 adults with AFib and hypertension (average age 68, 41% women), all of whom had catheter ablation at three hospitals in China. Half were assigned to sacubitril/valsartan and half to valsartan alone. After 12 months, documented arrhythmia recurred in 18% of the sacubitril/valsartan group compared with 28.3% in the valsartan group.

Both groups achieved similar reductions in blood pressure — about 10 mm Hg systolic. The rhythm benefit of sacubitril/valsartan therefore appears to go beyond blood pressure control. The lead author noted that long-term AFib management must combine rhythm treatment with management of cardiovascular risk factors, especially hypertension.

These results are from a conference abstract and have not yet been peer-reviewed. If you experience an irregular heartbeat, chest discomfort, or unexplained shortness of breath, consult a cardiologist rather than adjusting your own medication.

Source: American Heart Association Scientific Sessions 2026 · Read the original source ↗

Share this news

Comments · 0

No comments yet. Be the first!

More news